JY
LRMR icon

Jeff Yass’s Larimar Therapeutics LRMR Stock Holding History

Jeff Yass’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$1.58M Buy
518,300
+335,300
+183% +$1.33M ﹤0.01% 7033
2026
Q1 		$824K Buy
+183,000
New +$731K ﹤0.01% 8406
2025
Q4 		– Sell
-35,000
Closed -$113K – 13067
2025
Q3 		$113K Buy
35,000
+11,300
+48% +$42.4K ﹤0.01% 11485
2025
Q2 		$68.5K Sell
23,700
-29,100
-55% -$67.4K ﹤0.01% 11996
2025
Q1 		$114K Buy
52,800
+39,300
+291% +$124K ﹤0.01% 11455
2024
Q4 		$52.2K Sell
13,500
-33,400
-71% -$220K ﹤0.01% 11653
2024
Q3 		$307K Buy
46,900
+10,300
+28% +$82.8K ﹤0.01% 9548
2024
Q2 		$265K Buy
36,600
+10,800
+42% +$82.7K ﹤0.01% 9735
2024
Q1 		$196K Buy
+25,800
New +$201K ﹤0.01% 10611
2022
Q4 		– Sell
-15,300
Closed -$49K – 13139
2022
Q3 		$49K Buy
+15,300
New +$38.3K ﹤0.01% 12216
2019
Q2 		– Sell
-2,283
Closed -$75K – 10580
2019
Q1 		$75K Buy
+2,283
New +$117K ﹤0.01% 8352
2018
Q4 		– Sell
-900
Closed -$126K – 9520
2018
Q3 		$126K Buy
+900
New +$109K ﹤0.01% 8507
2018
Q2 		– Sell
-975
Closed -$87K – 10042
2018
Q1 		$87K Buy
+975
New +$82.6K ﹤0.01% 8750
2017
Q3 		– Sell
-2,742
Closed -$115K – 9278
2017
Q2 		$115K Sell
2,742
-125
-4% -$6.39K ﹤0.01% 8622
2017
Q1 		$160K Buy
2,867
+900
+46% +$44.7K ﹤0.01% 8156
2016
Q4 		$75K Sell
1,967
-2,675
-58% -$108K ﹤0.01% 9187
2016
Q3 		$184K Buy
4,642
+1,459
+46% +$66.3K ﹤0.01% 7640
2016
Q2 		$229K Sell
3,183
-375
-11% -$29.6K ﹤0.01% 7380
2016
Q1 		$285K Sell
3,558
-4,025
-53% -$318K ﹤0.01% 7343
2015
Q4 		$572K Buy
7,583
+2,675
+55% +$430K ﹤0.01% 6512
2015
Q3 		$1.88M Buy
4,908
+4,200
+593% +$1.89M ﹤0.01% 4389
2015
Q2 		$294K Buy
+708
New +$296K ﹤0.01% 8572

Other funds holding LRMR

DM
Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $665M AUM 95.48% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $747M AUM
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $524M AUM 164.42% 1-Year Est. Return

Jeff Yass's LRMR Position: Q2 2026 in Review

Jeff Yass increased its Larimar Therapeutics (LRMR) stake by 3.1% in Q2 2026, buying an estimated $17.3K and bringing the position to 144,428 shares worth $441K. The position accounts for ﹤0.01% of the portfolio, ranked #10201.

Jeff Yass first reported a position in LRMR in Q1 2015 and has held it in 30 quarters since. The position peaked at $1.29M in Q3 2015. 161 funds tracked by Wall St. Rank hold LRMR as of Q2 2026.

  • Jeff Yass held 144,428 shares of Larimar Therapeutics worth $441K as of Q2 2026.
  • Jeff Yass bought 4,368 Larimar Therapeutics shares in Q2 2026, an estimated $17.3K.
  • Larimar Therapeutics made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #10201 holding.
  • Jeff Yass first reported a position in Larimar Therapeutics in Q1 2015 and has held it in 30 quarters since.
  • Jeff Yass's Larimar Therapeutics position peaked at $1.29M in Q3 2015.
  • 161 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.